Open-label trial to evaluate the efficacy of pre-emptive therapy with minocycline and multidisciplinary intervention for skin toxicity of anti EGFR antibody in colorectal cancer patient

ABSTRACT: Interventions: Minocycline tablet 100mg once a day after dinner (for 4 weeks after the day starting to take anti EGFR antibody) Primary outcome(s): The incidence of >= Grade 2 skin toxicity (Dermatitis acneiform, Paronychia, Dry skin, Pruritus) during 4weeks after starting anti EGFR antibody (using CTCAE v4.0) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2625494 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR